Inspyr Therapeutics (NSPX): FY GAAP EPS of -$0.14.Cash and restricted cash was $0.4 million and $0.02 million at December 31, 2020 and 2019, respectively.Press Release For further details see: Inspyr Therapeutics reports FY results
Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds Lead asset, RT-AR001, pre-IND filing is on track for the first half of 2021 ...
WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual ...
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focuse...
Expansion of patent portfolio of novel adenosine immuno-modulator compounds WESTLAKE VILLAGE, CA / ACCESSWIRE / December 10, 2020 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for ...
Inspyr Therapeutics, Inc. (NSPX): Q3 GAAP EPS of $0.00.Cash of ~$0.03M.Press Release For further details see: Inspyr Therapeutics, Inc. reports Q3 results
Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds Increased Cash Runway by Securing $500,000 of Gross Proceeds From an Existing In...
Inspyr Therapeutics (NSPX) acquires a novel immuno-oncology delivery technology targeting adenosine receptor antagonists for the treatment of cancer. The technology was previously acquired by Inspyr and then licensed to Ridgeway Therapeutics.Inspyr has reacquired all rights previously li...
Preclinical data demonstrated delayed tumor growth, reduces metastases and anti-tumor immune response WESTLAKE VILLAGE, CA / ACCESSWIRE / October 9, 2020 / Inspyr Therapeutics, Inc. (OTC/PINK:NSPX), announces that it has acquired a novel immuno-oncology delivery technology targeting ad...
News, Short Squeeze, Breakout and More Instantly...
Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds Lead asset, RT-AR001, pre-IND filing is on track for the first half of 2021 ...
WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual ...
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focuse...